GC Green Cross announced on the 11th that it presented the current status of its development of therapies for lysosomal storage disorders (LSDs) at the WORLD Symposium 2026, held in San Diego, United States, from February 2 to 6.


Green Cross Corporation Shares Progress on Development of Therapies for Lysosomal Storage Disorders at 'WORLD Symposium 2026'

Green Cross Corporation Shares Progress on Development of Therapies for Lysosomal Storage Disorders at 'WORLD Symposium 2026'

View original image

At the symposium, GC Green Cross gave a poster presentation on the non-clinical results of its candidate therapy for Sanfilippo syndrome type A (MPS IIIA), GC1130A. Sanfilippo syndrome is a disease caused by a genetic defect that leads to the accumulation of heparan sulfate in the body and is accompanied by severe brain damage. To enhance the therapeutic effect of GC1130A, GC Green Cross is developing it using an intracerebroventricular (ICV) administration method that delivers the drug directly into the cerebral ventricles.


According to the results of non-clinical animal studies, levels of heparan sulfate in the brains of disease animal models administered GC1130A decreased significantly, and reductions in brain inflammation and improvements in cognitive function were confirmed. In the Morris water maze test conducted to assess cognitive function, disease animal models treated with GC1130A showed recovery of learning and memory abilities to a level similar to that of normal mice.


GC1130A is currently in Phase 1 clinical trials in the United States and Korea. It has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The company plans to complete the Phase 1 trial this year and is targeting commercialization before 2030.


GC Green Cross also participated in the global Phase 1/2 investigator meeting for the Fabry disease therapeutic candidate GC1134A (HM15421), where it shared safety parameters for Cohort 1 subjects, as well as preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data, and discussed future clinical strategies.


Fabry disease is a progressive, rare, and intractable disorder inherited via sex chromosomes, caused by a deficiency of the lysosomal enzyme alpha-galactosidase A, which breaks down glycolipids. When glycolipids that cannot be processed in the body continue to accumulate, they trigger cellular toxicity and inflammatory responses, leading to gradual damage to various organs and, in severe cases, death.


With enrollment for Cohort 1 of the global Phase 1/2 study of GC1134A now complete, the company plans to begin full-scale enrollment of Cohort 2 subjects in the second quarter. In addition to MSSI outcomes assessed by physicians, the company aims to evaluate the drug’s effects from multiple perspectives by also considering improvements in systemic pain relief and gastrointestinal symptoms confirmed in patient-reported outcomes (PROs).


Shin Soo-kyung, Head of Medical Affairs at GC Green Cross, said, "Through discussions with global experts at the symposium, we were able to once again confirm the potential of our lysosomal storage disorder pipeline under development," adding, "We will accelerate the ongoing global clinical trials to provide new treatment options for patients with rare diseases."



Meanwhile, GC1134A (HM15421), a Fabry disease treatment jointly developed by GC Green Cross and Hanmi Pharmaceutical, is being developed as a once-monthly subcutaneous (SC) injection formulation that improves dosing convenience compared with the existing once-every-two-weeks intravenous (IV) formulation, with the goal of becoming a best-in-class drug within its category.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing